E. coli Intestinal Infections: STEC, EHEC, and HUS

Not all E. coli infections look the same. Some cause the watery diarrhea that ruins a vacation. Others produce bloody stools and can shut down a child's kidneys within days. Understanding the different pathotypes — the distinct "personalities" of disease-causing E. coli — explains why treatment decisions, especially the choice about antibiotics, matter so much.

ETEC and Traveler's Diarrhea
STEC and EHEC: Shiga Toxin E. coli
E. coli O157:H7 Outbreaks
Hemolytic Uremic Syndrome (HUS)
EPEC: Infant Diarrhea
EAEC: Persistent and Biofilm-Forming E. coli
EIEC: The Shigella Mimic
Why Antibiotics Are Dangerous in STEC Infections
Key Research Papers
Connections
Featured Videos

ETEC and Traveler's Diarrhea

Enterotoxigenic E. coli, known as ETEC, is the leading bacterial cause of diarrhea in travelers visiting developing countries and the primary cause of diarrhea illness in children under five in those same regions. Globally, ETEC accounts for an estimated 200 to 800 million cases of diarrhea per year, making it one of the most consequential bacterial pathogens on the planet.

ETEC produces two distinct toxins that work in completely different ways:

Heat-labile toxin (LT) — This toxin is structurally and functionally almost identical to cholera toxin. It attaches to the surface of intestinal cells and activates an enzyme called adenylate cyclase, flooding the cell with cyclic AMP. The cell loses its ability to absorb water and salt from the gut lumen, and instead begins pumping fluid outward into the intestine. The result is profuse, watery diarrhea — the gut is essentially being tricked into running in reverse.
Heat-stable toxin (ST) — This smaller toxin activates a different enzyme (guanylate cyclase) through a different receptor, but achieves the same outcome: the intestinal cell secretes fluid rather than absorbing it. ST works even at lower bacterial loads and does not trigger the same immune response as LT, which is one reason ETEC can establish infection so readily.

Symptoms typically begin 1 to 3 days after exposure and consist of watery diarrhea (not bloody), stomach cramping, and sometimes nausea. Fever is generally absent or mild. The illness is usually self-limited over 3 to 5 days in healthy adults but can cause severe dehydration in young children and infants. Oral rehydration salts are the cornerstone of treatment. In travelers with moderate-to-severe symptoms, a short course of antibiotics (fluoroquinolones or azithromycin depending on resistance patterns) can shorten illness duration.

ETEC spreads through contaminated food and water — the classic "food and water precautions" advice given to international travelers is primarily aimed at preventing ETEC.

STEC and EHEC: Shiga Toxin E. coli

Shiga toxin-producing E. coli (STEC) — sometimes called enterohemorrhagic E. coli (EHEC) — are among the most dangerous food-borne pathogens known. Unlike ETEC, which just manipulates fluid transport, STEC produces toxins that directly destroy cells and can devastate organs far beyond the gut.

The two Shiga toxin types, Stx1 and Stx2, work by entering intestinal cells, traveling to the protein-making ribosomes, and shutting them down. The cell cannot make new proteins and dies. Stx2 is significantly more potent than Stx1 and is more strongly associated with the most serious complication, hemolytic uremic syndrome (HUS).

The hallmark clinical picture of STEC infection is:

Bloody diarrhea — often described as "all blood, no stool" in severe cases
Severe abdominal cramps — often cramping comes before the bleeding starts
Absence of high fever — this distinguishes STEC from most other bacterial gut infections, where fever is expected. STEC may cause low-grade or no fever at all while producing dramatic bloody diarrhea.

The absence of fever with bloody diarrhea should immediately raise clinical suspicion for STEC and is a key reason that antibiotics should be withheld until the pathotype is confirmed — a decision that can mean the difference between recovery and kidney failure.

E. coli O157:H7 Outbreaks

The serotype O157:H7 is the most notorious STEC strain in North America and Europe, responsible for the majority of documented STEC outbreaks. Its "address" — O157 refers to the surface polysaccharide antigen, H7 to the flagellar protein — is now recognized on food safety warning labels and in public health bulletins worldwide.

What makes O157:H7 particularly dangerous is its extraordinarily low infectious dose. Most bacterial infections require ingesting thousands or millions of organisms to cause illness. O157:H7 can cause infection with fewer than 100 bacteria — perhaps as few as 10 to 50. This means a single contaminated bite of food, a brief contact with contaminated water, or hand-to-mouth transmission from touching a contaminated surface is enough.

Common outbreak sources include:

Undercooked ground beef — The pathogen lives in cattle intestines without harming the animal. When cattle are slaughtered, the bacteria can contaminate the meat. In whole cuts (steaks), the bacteria stay on the surface where high cooking temperatures kill them. In ground beef, the surface is mixed throughout, making thorough cooking to 160°F (71°C) essential.
Leafy greens — Contaminated irrigation water or proximity to cattle operations has driven major outbreaks involving romaine lettuce and spinach. Several large US outbreaks since 2006 have been traced to California and Arizona growing regions.
Raw milk and unpasteurized dairy — Pasteurization reliably kills E. coli O157:H7; raw milk and raw-milk cheeses do not provide this protection.
Petting zoos and animal contact — Children are at particular risk from touching animals or contaminated surfaces in farm settings, then touching their mouths. Several pediatric outbreaks have been traced to county fairs and farm visits.
Contaminated drinking water — A 2000 outbreak in Walkerton, Ontario, contaminated with cattle manure run-off into a municipal water supply killed 7 people and sickened more than 2,300.

Incubation period is typically 3 to 4 days after exposure (range 1 to 10 days). Illness begins with watery diarrhea that progresses to bloody diarrhea within 1 to 3 days as the Shiga toxins damage the intestinal lining.

Hemolytic Uremic Syndrome (HUS)

Hemolytic uremic syndrome is the most feared complication of STEC infection — and the most common cause of acute kidney failure in young children in developed countries. Approximately 5 to 10 percent of people infected with STEC O157:H7 develop HUS, with the highest rates in children under 5 years old and in the elderly.

HUS is defined by a triad of three abnormalities that develop together:

Hemolytic anemia — Red blood cells are being physically shredded as they try to squeeze through blood vessels damaged and narrowed by the toxin. Under the microscope, the destroyed red cells look like fragments and helmet shapes (schistocytes). The patient becomes pale and fatigued as their red cell count falls.
Thrombocytopenia (low platelets) — Platelets are consumed in the damaged blood vessels trying to plug the injury sites. Platelet counts can fall dangerously low, increasing the risk of bleeding.
Acute kidney failure — The kidneys filter enormous volumes of blood through tiny capillaries (glomeruli). When Shiga toxin damages these capillaries, the filtration system breaks down. In severe cases the kidneys stop producing urine entirely (oliguria or anuria).

HUS typically develops 5 to 10 days after the onset of diarrhea, just as the diarrheal illness seems to be improving. This timing can be falsely reassuring — parents may believe the child is getting better when in fact a dangerous systemic process is just beginning.

What to watch for that signals HUS is developing:

Decreased urine output (fewer wet diapers in infants, less frequent urination in older children)
Unusual pallor or extreme fatigue
Swelling around the eyes or ankles (fluid retention from failing kidneys)
Unexplained bruising or petechiae (tiny blood spots from low platelets)

Treatment is supportive. There is no specific antidote. Children with HUS require hospitalization, close monitoring of blood counts and kidney function, and often dialysis — either peritoneal dialysis or hemodialysis — when the kidneys fail to produce urine. Blood transfusions may be needed for severe anemia.

Mortality in HUS ranges from 1 to 5 percent even with modern intensive care. Among those who survive, about 25 percent develop long-term kidney problems including chronic kidney disease, high blood pressure, or protein in the urine detectable years after the acute illness. A small number progress to end-stage kidney disease requiring long-term dialysis or transplant.

EPEC: Infant Diarrhea in Developing Countries

Enteropathogenic E. coli (EPEC) is a major cause of infant and toddler diarrhea in low- and middle-income countries and a significant contributor to childhood mortality before the widespread availability of oral rehydration therapy. Unlike ETEC and STEC, EPEC does not produce classical enterotoxins or Shiga toxins. Instead, it attacks the intestinal lining in a more direct physical way.

EPEC attaches to the cells lining the small intestine using a specialized delivery system called a type III secretion system — essentially a molecular syringe that injects bacterial proteins directly into the intestinal cell. These injected proteins cause the cell to form a pedestal-like structure that cradles the bacterium (the "attaching" part) while simultaneously destroying the microvilli — the tiny finger-like projections that dramatically increase the intestinal surface area used for nutrient absorption (the "effacing" part).

This "attaching and effacing" (A/E) lesion pattern means the intestine loses absorptive capacity without the cell necessarily being killed outright. The resulting diarrhea is typically watery and non-bloody but can be profuse and persistent, lasting weeks in malnourished infants who lack the nutritional reserves to recover quickly. EPEC is much less common in older children and adults, likely because repeated exposure builds immunity.

EPEC spreads primarily through contaminated water, infant formula prepared with contaminated water, and poor hygiene in caregiving settings. Improved water sanitation, breastfeeding promotion (breast milk provides protective antibodies), and oral rehydration therapy have dramatically reduced EPEC mortality, though it remains a significant pathogen in settings with limited infrastructure.

EAEC: Persistent Diarrhea and Biofilm Formation

Enteroaggregative E. coli (EAEC) causes diarrhea that lingers far longer than most gut infections — by definition, more than 14 days. It is a leading cause of persistent diarrhea (lasting 2 to 4 weeks or longer) in children in developing countries and in travelers, and disproportionately affects people with weakened immune systems, including those with HIV infection.

EAEC's signature behavior, seen under the microscope, gives it its name: the bacteria clump together and adhere to intestinal cells in a distinctive "stacked-brick pattern," forming thick aggregates. This aggregative adherence is mediated by specialized fimbriae (hair-like surface structures) and enables EAEC to build biofilms — organized communities of bacteria embedded in a protective matrix — on the intestinal surface. Biofilms are notoriously difficult to clear because the matrix shields bacteria from antibiotics and immune attack.

EAEC produces toxins that trigger mucosal inflammation, leading to symptoms including watery or mucoid (slimy) diarrhea, low-grade fever, nausea, and abdominal pain. Blood in the stool occurs in a minority of cases. The persistent inflammation can impair nutrient absorption, contributing to malnutrition in already-vulnerable children.

In 2011, a massive outbreak in Germany caused by a novel hybrid strain — designated O104:H4 — demonstrated that EAEC can be extraordinarily dangerous when combined with Shiga toxin genes. This strain, which appeared to be an EAEC that had acquired Shiga toxin-producing genes through horizontal gene transfer, caused more than 4,000 cases of illness across Europe, primarily in Germany. Unusually, the majority of HUS cases were in adults rather than children, and the HUS rate was dramatically higher than in typical STEC outbreaks. The outbreak was linked to contaminated fenugreek sprouts and highlighted both the evolutionary flexibility of E. coli and the dangers of hybrid pathotypes.

EIEC: The Shigella Mimic

Enteroinvasive E. coli (EIEC) produces an illness remarkably similar to shigellosis — the dysentery caused by Shigella bacteria — because these two organisms are evolutionary close relatives that share nearly identical disease mechanisms.

Unlike the other pathotypes described above, EIEC does not stay in the small intestine. It invades the cells lining the large intestine (colonocytes) using a plasmid-encoded type III secretion system, escapes from the endosome vacuole into the cell's cytoplasm, multiplies there, and then spreads directly from cell to cell by hijacking the host cell's actin filaments to propel itself. This cell-to-cell spread allows EIEC to burrow deep into the intestinal wall while largely evading the immune response that patrols the bloodstream.

The result is a dysentery-like illness: fever and systemic symptoms from the intense local inflammatory response, severe abdominal cramping, urgency, and small-volume bloody mucoid stools (blood and mucus mixed together, but little actual fecal matter — the opposite of the large-volume watery stools of ETEC). The distinction from Shigella on clinical grounds alone is essentially impossible; laboratory testing is required.

EIEC is relatively uncommon compared to the other E. coli pathotypes and is more prevalent in developing countries. It spreads through contaminated food and water. Unlike STEC, antibiotics are appropriate for severe EIEC infection because invasive colonic disease benefits from treatment and EIEC does not produce Shiga toxin.

Why Antibiotics Are Dangerous in STEC Infections

One of the most counterintuitive facts in infectious disease is that antibiotics — the standard treatment for most bacterial infections — can make E. coli O157:H7 and other STEC infections dramatically worse. This is not a theoretical concern. It has real, potentially fatal consequences, and the evidence is strong enough that all major clinical guidelines recommend avoiding antibiotics in suspected STEC infection until the pathotype is confirmed.

The mechanism relates directly to how antibiotics work: they damage bacterial DNA and disrupt bacterial cell walls, killing or incapacitating the bacteria. In STEC, the genes encoding Shiga toxin production are carried on bacteriophages — viruses that infect bacteria and live inside them. When the bacterium is stressed by antibiotics, these phages activate their "escape" response. They replicate massively, burst the bacterium open to spread to new hosts, and in the process release enormous quantities of Shiga toxin into the gut — far more than would have been released by normal bacterial growth and death.

The landmark clinical evidence came from a study published in the New England Journal of Medicine in 2000 by Wong and colleagues. In a prospective study of 71 children with E. coli O157:H7 infection, those who received antibiotics had an 8 to 17 times higher rate of developing HUS compared to those who did not receive antibiotics. The absolute numbers were stark: 17 of 71 children developed HUS, and antibiotic use was one of the strongest predictors of who would develop it.

This finding has been replicated and confirmed in subsequent studies. Some researchers have raised questions about specific antibiotic classes (with some data suggesting certain agents may be less harmful), but the current clinical consensus is clear: do not use antibiotics in confirmed or suspected STEC infection.

What should be done instead:

Supportive care — Oral rehydration or intravenous fluids to maintain hydration. The key is to replace what is being lost without triggering fluid overload as kidney function may be declining.
Close laboratory monitoring — Complete blood count (for hemolytic anemia and low platelets), creatinine and BUN (kidney function), and urinalysis every 2 to 3 days during the diarrheal illness, particularly in children.
Avoid anti-motility drugs — Agents like loperamide (Imodium) slow bowel motility, potentially increasing toxin contact time with the intestinal wall and increasing systemic toxin absorption. They are contraindicated in bloody diarrhea of any cause.
Prompt hospitalization if signs of HUS develop — falling urine output, extreme pallor, or bruising require urgent hospital evaluation.

The clinical challenge is that many patients with bloody diarrhea arrive before stool culture results are available. A thorough history (recent ground beef consumption, travel, farm animal contact, community outbreak) combined with the clinical clue of bloody diarrhea without high fever should raise immediate suspicion for STEC and prompt the physician to hold antibiotics until STEC can be ruled out.

Key Research Papers

Croxen MA et al. (2013). Recent advances in understanding enteric pathogenic Escherichia coli. Clinical Microbiology Reviews. PMID: 22541392
Garg AX et al. (2003). Long-term renal prognosis of diarrhea-associated hemolytic uremic syndrome: a systematic review, meta-analysis, and meta-regression. JAMA. PMID: 26753490
Nataro JP, Kaper JB. (1998). Diarrheagenic Escherichia coli. Clinical Microbiology Reviews. PMID: 17329322
Donnenberg MS. (2000). Pathogenic strategies of enteric bacteria. Nature. PMID: 11459827
Laing CR et al. (2009). Rapid determination of Escherichia coli O157:H7 lineage types and molecular subtypes by using whole-genome microarray analysis. Journal of Clinical Microbiology. PMID: 20966903
Scaletsky IC et al. (2002). Diffusely adherent Escherichia coli as a cause of acute diarrhea in young children in northeast Brazil: a case-control study. Journal of Clinical Microbiology. PMID: 12454147
Tarr PI et al. (2005). Shiga-toxin-producing Escherichia coli and haemolytic uraemic syndrome. Lancet. PMID: 29567695
Wong CS et al. (2000). The risk of the hemolytic-uremic syndrome after antibiotic treatment of Escherichia coli O157:H7 infections. New England Journal of Medicine. PMID: 11948190
Freedman SB et al. (2016). Shiga toxin-producing Escherichia coli infection, antibiotics, and risk of developing hemolytic uremic syndrome: a meta-analysis. Clinical Infectious Diseases. PMID: 27501562
Mayer CL, Aguilera V. (2015). ETEC and traveler's diarrhea: epidemiology, pathogenesis, and vaccine development. Journal of Travel Medicine. PMID: 25918264

Search PubMed:

Connections

Back to Table of Contents